Pharma has a new playbook—and it’s not always about new science.
In a world where “innovation” is the currency of premium pricing, drugmakers increasingly justify higher costs for repurposed medicines using a familiar narrative: same molecule, new valu…

Russia’s “third wheel” rule is supposed to be a footnote in the global drug supply chain. But the real story is what happens when patent filings stop being paperwork—and start acting like an early-warning system.
In a world where APIs (active pharmaceu…

Europe’s patent system is supposed to be a referee—not a maze. But a new analysis from DrugPatentWatch highlights a strategy that’s turning the “final decision” into a moving target: divisional patent applications. In plain terms, big pharma can keep d…

Pharma patent litigation used to be a $50M problem.
Now, for some companies, it’s closer to $5M.
That’s not a typo—and it’s not just “better lawyering.” It’s a shift in how drug developers think about patent risk: earlier, more surgical, and far more o…

PBMs and rebates aren’t “background noise” in pharma—they’re the operating system.
If you’re a pharma executive, payer strategy isn’t just a slide deck topic anymore. It’s the difference between a launch that scales and a launch that stalls quietly i…

Mark Cuban’s cost-plus pricing isn’t just another pricing headline—it’s a direct challenge to the patent playbook that has quietly governed U.S. drug economics for decades.
Here’s the agitation: for years, the industry’s story has been consistent. Pate…

Should you file a provisional patent for your drug invention? The honest answer is: it depends—on timing, strategy, and what you’re actually trying to protect.
In life sciences, “file now, think later” sounds safe. But in patent strategy, speed without…

Don’t Wait for the Patent Cliff. Build Supply-Chain Resilience Years Before Drug Patent Expiration.
The “patent cliff” isn’t a cliff you can see coming from the next room. It’s a slow-motion event—one that can quietly reshape pricing, manufacturing cap…

The 180-Day FDA Exclusivity Race Isn’t a Sprint—It’s a Strategy War. Here’s the Playbook.
If you’re in generic or biosimilar development, you already know the headline: the first applicant to win the “180-day exclusivity” clock can capture outsized mar…

Pharmacy benefit managers (PBMs) have become the quiet center of gravity in U.S. drug pricing—shaping what patients pay, what pharmacies dispense, and what manufacturers ultimately earn. Yet the conversation still sounds like it’s stuck in the same loo…